Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Koningstein, Maike ^a   Van Der Bij, Akke K ^a,b   De Kraker, Marlieke E A ^a   Monen, Jos C ^a   Muilwijk, Jan ^a   De Greeff, Sabine C ^a   Geerlings, Suzanne E ^c   Leverstein Van Hall, Maurine A ^a,d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c Center for Infection and Immunity Amsterdam   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN; PROTEUS MIRABILIS; URINARY TRACT INFECTION; UROSEPSIS; BACTERIA; COMPLICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HEALTH CARE PLANNING; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROBABILITY; STATISTICS AND NUMERICAL DATA; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; HEALTH PLANNING GUIDELINES; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; PROBABILITY; URINARY TRACT INFECTIONS;

EID: 84900320658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086634     Document Type: Article

References (29)

1. van der Kooi TI, Mannien J, Wille JC, van Benthem BH (2010) Prevalence of nosocomial infections in The Netherlands, 2007-2008: results of the first four national studies. J Hosp Infect 75: 168-172.
2. Wagenlehner FM, Naber KG (2006) Treatment of bacterial urinary tract infections: presence and future. Eur Urol 49: 235-244. (Pubitemid 43197859)
3. Geerlings SE, van den Broek PJ, van Haarst EP, Vleming LJ, van Haaren KM, et al. (2006) Optimisation of the antibiotic policy in the Netherlands. The SWAB guideline for antimicrobial treatment of complicated urinary tract infections [In Dutch]. Ned Tijdschr Geneeskd 150: 2370-2376. (Pubitemid 44702103)
4. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA (2004) Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis 190: 1739-1744. (Pubitemid 39487816)
5. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, et al. (2000) Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 30: 473-478. (Pubitemid 30205291)
6. O'Brien TF, Stelling J (2011) Integrated Multilevel Surveillance of the World's Infecting Microbes and Their Resistance to Antimicrobial Agents. Clin Microbiol Rev 24: 281-295.
7. Masterton R (2008) The Importance and Future of Antimicrobial Surveillance Studies. Clin Infect Dis. 47: S21-S31.
8. Pitout JDD (2009) Recent changes in the epidemiology and management of extended-spectrum b-lactamase-producing Enterobacteriaceae. F1000 Med Rep 1: pii: 84.
9. Paterson DL (2006) Resistance in Gram-Negative Bacteria: Enterobacteriaceae. Am J Med 119: S20-S28.
10. Stichting Werkgroep Antibioticabeleid. Optimalization of the antibiotic policy in the Netherlands: SWAB guidelines for antimicrobial therapy of complicated urinary tract infections. http://www.swab.nl/swab/cms3.nsf/uploads/ 7F074B1D12F0BA58C1257A9B002EA041/$FILE/Revised%20UTI%20Guidelines.pdf (5 March 2013, date last accessed).
11. den Heijer CD, Donker GA, Maes J, Stobberingh EE (2010) Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother 65: 2128-2133.
12. Kahlmeter G (2003) Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 22: S2 49-52.
13. Gupta K, Sahm DF, Mayfield D, Stamm WE (2001) Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 33: 89-94. (Pubitemid 32554508)
14. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, et al. (2000) Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30: 454-460. (Pubitemid 30205288)
15. van der Bij AK, van Dijk K, Muilwijk J, Thijsen SF, Notermans DW, et al.(2012) Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clin Microbiol Infect 18: E466-E472.
16. Orenstein R, Wong ES (1999) Urinary tract infections in adults. Am Fam Physician 59: 1225-1234, 1237.
17. Archibald L, Phillips L, Monnet D, McGowan JE Jr., et al (1997) Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 24: 211-215. (Pubitemid 27081545)
18. Fridkin SK, Gaynes RP (1999) Antimicrobial resistance in intensive care units. Clin Chest Med 20: 303-316, viii. (Pubitemid 29283545)
19. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB (2007) Investigation of sources of potential bias in laboratory surveillance for anti-microbial resistance. Clin Invest Med 30: E159-166. (Pubitemid 350075004)
20. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, et al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19: 141-60.
21. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002) Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 46: 2540-2545. (Pubitemid 34793461)
22. Alos JI, Serrano MG, Gomez-Garces JL, Perianes J (2005) Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 11: 199-203.
23. Zuschneid I, Rucker G, Schoop R, Beyersmann J, Schumacher M, et al. (2010) Representativeness of the surveillance data in the intensive care unit component of the German nosocomial infections surveillance system. Infect Control Hosp Epidemiol 31: 934-938.
24. Nicolle LE (2013) Urinary tract infection. Crit Care Clin 29: 699-715.
25. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, et al. (2011) International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103-e120.
26. Stichting Werkgroep Antibiotica Beleid & National Insitute for Public Health and the Environment (2013) Nethmap 2013. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands . RIVM, Bilthoven, The Netherlands.
27. European Centre for Disease Prevention and Control (2012) Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm, Sweden.
28. Edson RS, Terrell CL (1999) The aminoglycosides. Mayo Clin Proc 74: 519-28. (Pubitemid 29207153)
29. Gonzalez LS, Spencer JP (1998) Aminoglycosides: a practical review. 58: 1811-20.